Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer Inc. (NYSE: PFE) has appointed Aamir Malik as the new Executive Vice President and Chief Business Innovation Officer, effective August 30, 2021. Malik, previously a Managing Partner at McKinsey & Company, will report to CEO Albert Bourla and succeed John Young as he retires after 34 years. In his new role, Malik will be responsible for the company’s strategy, business development, and innovative partnerships globally. Bourla highlighted Malik's extensive experience in driving growth and improving patient care during the announcement.
Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have signed a letter of intent with Eurofarma Laboratórios SA to manufacture their COVID-19 vaccine, COMIRNATY®, for distribution in Latin America. Eurofarma will initiate technical transfer and on-site development immediately, with finished dose production expected to exceed 100 million doses annually, beginning in 2022. This collaboration aims to enhance equitable access to vaccines in the region, contributing to a total of 3 billion doses planned for global distribution by year-end 2021.
Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) announced the initiation of a supplemental Biologics License Application for a third dose of COMIRNATY. New Phase 3 trial data show the booster dose significantly increases SARS-CoV-2 neutralizing antibody titers, achieving levels 3.3 times higher than the second dose. The companies plan to submit these findings to the European Medicines Agency and other regulatory bodies shortly. Adverse events observed were mild to moderate, with a low incidence of severe reactions, consistent with previous clinical data.
Pfizer and BioNTech received FDA approval for COMIRNATY®, making it the first FDA-approved COVID-19 vaccine for individuals aged 16 and older. This vaccine has been available under Emergency Use Authorization since December 2020. The approval validates the vaccine's efficacy and safety, supported by long-term Phase 3 trial data. Approximately 60% of eligible Americans are fully vaccinated, and the companies aim to enhance vaccine confidence. COMIRNATY is also authorized for individuals aged 12-15 under EUA and will seek further approvals for booster doses and younger age groups.
Pfizer (NYSE: PFE) has announced its definitive agreement to acquire Trillium Therapeutics (NASDAQ/TSX: TRIL) for an equity value of $2.26 billion, equating to $18.50 per share, marking a significant 118% premium. The acquisition aims to enhance Pfizer's oncology portfolio, especially in treating blood cancers, by integrating Trillium's lead molecules, TTI-622 and TTI-621, which target the SIRPα-CD47 axis. These molecules are in advanced clinical trials and show promise as therapies for various hematological malignancies.
Pfizer Inc. (NYSE: PFE) has received approval from the European Commission for XELJANZ® (tofacitinib) for treating active polyarticular juvenile idiopathic arthritis (JIA) and juvenile psoriatic arthritis (PsA) in patients aged two years and older who have not responded adequately to previous disease-modifying antirheumatic drug (DMARD) therapies. The approval includes a new oral solution and a once-daily tablet formulation. XELJANZ is the first JAK inhibitor approved in Europe for these indications and has been studied across over 50 clinical trials globally.
Summary not available.
Pfizer (PFE) and BioNTech (BNTX) have submitted Phase 1 data to the FDA for a booster dose of their COVID-19 vaccine (BNT162b2). This submission follows successful Phase 1 trials showing significantly higher neutralizing antibodies after a third dose compared to the two-dose schedule. The companies plan to also submit this data to the EMA and other authorities soon. Although the booster is not yet widely authorized in the U.S., it was recently approved for immunocompromised individuals. Further Phase 3 results are expected shortly.
Pfizer Inc. (NYSE:PFE) has received FDA approval for TICOVAC™, a vaccine for tick-borne encephalitis (TBE), aimed at individuals aged 1 and older. This makes TICOVAC™ the first FDA-approved vaccine to protect U.S. residents traveling to TBE-endemic areas. With over 170 million doses distributed globally over the past 45 years, the vaccine shows a seropositivity rate of 99.5% in children and 98.7-100% in adults after three doses. While TBE is not endemic in the U.S., it poses significant health risks in over 35 countries worldwide.
Pfizer Inc. (NYSE: PFE) announced positive top-line results from the Phase 2b/3 ALLEGRO trial for ritlecitinib, an oral treatment for alopecia areata. The study met its primary endpoint, showing significant scalp hair regrowth in patients with at least 50% hair loss. Ritlecitinib’s safety profile was consistent with earlier studies, with common adverse events including nasopharyngitis and headache. There were no major adverse cardiac events reported. Full study results will be published, supporting future regulatory filings.